Nearly one in four employers in a recent KFF survey expressed their likelihood to cover the cost of anti-obesity medications, though most remain hesitant due to high costs and potential long-term reliance.
The KFF survey indicated that 62% of firms are unlikely to cover anti-obesity medications soon, primarily due to concerns over the significant prescription spending increase they might face.
Among the firms considering coverage, many require employees to also engage in lifestyle or weight loss programs to potentially decrease reliance on these medications in the future.
Interestingly, a separate survey from the Physicians Committee for Responsible Medicine revealed that 62% of Americans looking to lose weight prefer making dietary changes over taking injectable medications.
Collection
[
|
...
]